; Whereas Gavi has been a major contributor in reducing the number of childhood deaths in lower-income countries due to vaccine-preventable disease by 70 percent since 2000; Whereas country ownership and sustainability are at the core of the Gavi model, which requires Gavi-eligible countries to contribute to a portion of vaccine costs and directly invest in immunizing children, and Gavi-supported countries contributed more than $1,500,000,000 to immunization campaigns between 2008 and 2022; Whereas 78 low-income countries currently provide co-financing for new and underused vaccines supported by Gavi, more than 19 countries have transitioned from Gavi support by the end of 2022, and an additional 10 countries may transition by 2040, moving toward fully funding their immunization programs; Whereas Gavi has transformed the market for vaccines by matching pooled demand from low-income countries with secure, predictable financing to make vaccines more affordable and supply more reliable, reducing the price of the most common vaccines by 24 percent from 2015 to 2020 and increasing the number of global vaccine manufacturers selling pre-qualified Gavi-supported vaccines to the world’s most impoverished countries from 5 in 2001 to 18 in 2018; Whereas Gavi estimates that its market shaping efforts will result in savings of over $900,000,000 from 2021 to 2025 and may encourage research and development of new vaccines; Whereas Gavi is poised to provide the most comprehensive package of support in the 2021 to 2025 period by financing and delivering 18 vaccines to the world’s most impoverished countries; Whereas Gavi, the African Union, and the Africa Centers for Disease Control (Africa CDC) have jointly established the African Vaccine Manufacturing Accelerator (AVMA) to provide innovative financing to expand sustainably vaccine manufacturing capacity in Africa and improve the region’s resilience in the face of pandemics, outbreaks, and other health emergencies, while preserving the health of vaccine markets globally